Innate Pharma (IPHYF) Short term Debt (2017 - 2025)

Innate Pharma's Short term Debt history spans 9 years, with the latest figure at $10.2 million for Q4 2025.

  • For Q4 2025, Short term Debt rose 10.1% year-over-year to $10.2 million; the TTM value through Dec 2025 reached $10.2 million, up 10.1%, while the annual FY2025 figure was $10.2 million, 8.7% up from the prior year.
  • Short term Debt reached $10.2 million in Q4 2025 per IPHYF's latest filing, up from $9.3 million in the prior quarter.
  • In the past five years, Short term Debt ranged from a high of $35.2 million in Q4 2021 to a low of $2.1 million in Q4 2022.
  • Average Short term Debt over 5 years is $13.3 million, with a median of $9.6 million recorded in 2023.
  • Peak YoY movement for Short term Debt: skyrocketed 1277.31% in 2021, then crashed 93.9% in 2022.
  • A 5-year view of Short term Debt shows it stood at $35.2 million in 2021, then plummeted by 93.9% to $2.1 million in 2022, then surged by 348.33% to $9.6 million in 2023, then decreased by 3.21% to $9.3 million in 2024, then increased by 10.1% to $10.2 million in 2025.
  • Per Business Quant, the three most recent readings for IPHYF's Short term Debt are $10.2 million (Q4 2025), $9.3 million (Q4 2024), and $9.6 million (Q4 2023).